All In Biotech

Free tool

Drugs in development

Investigational drugs and biologics in industry-sponsored Phase 2 and Phase 3 trials that are active or finished in the last two years, and that FDA has not approved. Built from 10,322 ClinicalTrials.gov records, with code names and generic names merged. For approved drugs, use Drug Search.

Last checked: Nov 20, 2026Latest source record: rebuilt Nov 18, 2026Source: ClinicalTrials.govMethods & limitations

Drugs in development

3,685

Not FDA-approved

In Phase 3

1,424

Highest phase reached

Matching your filters

9

Reset

9 drugs in development

Names, sponsors and conditions come from the trial records. Click a drug for its trials.

  • FelzartamabPhase 38 trials

    Biogen · Antibody-mediated Rejection, Microvascular Inflammation, Graves' Disease

  • LitifilimabBIIB059Phase 35 trials

    Biogen · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus, Lupus Erythematosus, Systemic

  • SalanersenBIIB115Phase 33 trials

    Biogen · Muscular Atrophy, Spinal, Spinal Muscular Atrophy

  • DNL151BIIB122Phase 22 trials

    Denali Therapeutics Inc. · Parkinson Disease

  • KDS2010Phase 22 trials

    NeuroBiogen Co., Ltd · Overweight, Obesity, Obese Patients

  • BGC101autologous EnEPC preparationPhase 21 trial

    Biogen · Chronic Limb-Threatening Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease

  • BIIB091Phase 21 trial

    Biogen · Relapsing Forms of Multiple Sclerosis

  • BIIB147Phase 21 trial

    Biogen · Amyotrophic Lateral Sclerosis

  • DiranersenISIS 814907, BIIB080Phase 21 trial

    Biogen · Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.